157 related articles for article (PubMed ID: 34218581)
21. [Clinical outcomes of hematopoietic stem cell transplantation for angioimmunoblastic T-cell lymphoma].
Xu LM; Li NN; Wang Z; Wu XX; Dong YJ; Fu XR; Liu Y; Hu LD; Li XF; Wang YN; Wu YM; Ren HY; Zhang MZ; Wang MH; Li YH; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):573-577. PubMed ID: 32397020
[No Abstract] [Full Text] [Related]
22. [Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].
Solovyev MV; Mendeleeva LP; Pokrovskaya OS; Nareyko MV; Firsova MV; Galtseva IV; Davydova YO; Kapranov NM; Kuzmina LA; Gemdzhian EG; Savchenko VG
Ter Arkh; 2017; 89(7):25-31. PubMed ID: 28766537
[TBL] [Abstract][Full Text] [Related]
23. Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China.
Liu Y; Rao J; Li J; Wen Q; Wang S; Lou S; Yang T; Li B; Gao L; Zhang C; Kong P; Gao L; Wang M; Zhu L; Xiang X; Zhou S; Liu X; Peng X; Zhong J; Zhang X
Haematologica; 2021 Jan; 106(1):163-172. PubMed ID: 31780634
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
25. Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review.
Tian L; Li C; Sun J; Zhai Y; Wang J; Liu S; Jiang Y; Wu W; Xing D; Lv Y; Guo J; Xu H; Sun H; Li Y; Li L; Zhao Z
Front Immunol; 2022; 13():1041177. PubMed ID: 36733398
[TBL] [Abstract][Full Text] [Related]
26. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
27. [Analysis of treatment response and prognostic factors of T-LBL patients treated with pediatric-like ALL therapy following HSCT].
Wang HT; Dong Y; Gao XT; Wan Z; Zhao YX; Liu YM; Liu L
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):387-393. PubMed ID: 32536135
[No Abstract] [Full Text] [Related]
28. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
Cordas Dos Santos DM; Saliba RM; Patel R; Bashir Q; Saini N; Hosing C; Kebriaei P; Khouri IF; Nieto Y; Popat U; Ahmed H; Lee HC; Manasanch EE; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1077-1083. PubMed ID: 31786242
[TBL] [Abstract][Full Text] [Related]
29. [Study on Application of RVD Regimen Sequential Auto-HSCT in the Treatment of Multiple Myeloma Evaluated by Propensity Score Matching].
Wang Y; Xue Y; Fu CM; Feng K; Li XL; Duan YY; Zhang CX; Yang YJ; Shi H; Fu J; Meng YN; Wang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1150-1155. PubMed ID: 35981376
[TBL] [Abstract][Full Text] [Related]
30. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT.
Gagelmann N; Eikema DJ; de Wreede LC; Rambaldi A; Iacobelli S; Koster L; Caillot D; Blaise D; Remémyi P; Bulabois CE; Passweg J; Leleu X; Zver S; Kobbe G; Ljungman P; Chevallier P; Ringhoffer M; Martin M; Salmenniemi U; Poiré X; Lenhoff S; Pioltelli P; Mordini N; Delforge M; Garderet L; Schönland S; Yakoub-Agha I; Kröger N
Bone Marrow Transplant; 2021 Jan; 56(1):210-217. PubMed ID: 32710010
[TBL] [Abstract][Full Text] [Related]
31. [Autologous haematopoietic stem cell transplantation in patients with multiple myeloma complicated by dialysis-dependent renal failure].
Firsova MV; Mendeleeva LP; Solovev MV; Rekhtina IG; Pokrovskaya OS; Urnova ES; Soboleva NP; Dvirnyk VN; Klyasova GA; Kuzmina LA; Savchenko VG
Ter Arkh; 2020 Sep; 92(7):70-76. PubMed ID: 33346447
[TBL] [Abstract][Full Text] [Related]
32. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma.
Kawamura K; Tsukada N; Kanda Y; Ikeda T; Yoshida A; Ueda Y; Ishida T; Suzuki K; Murakami H
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1392-1398. PubMed ID: 29555314
[TBL] [Abstract][Full Text] [Related]
33. Salvage autologous hematopoietic stem cell transplantation for multiple myeloma performed with stem cells procured after previous high dose therapy - a multicenter report by the Polish Myeloma Study Group.
Drozd-Sokołowska J; Waszczuk-Gajda A; Biecek P; Kobylińska K; Mańko J; Hus I; Szmigielska-Kapłon A; Nowicki M; Romejko-Jarosińska J; Kozioł M; Sędzimirska M; Sachs W; Mądry K; Boguradzki P; Król M; Hus M; Basak G; Dwilewicz-Trojaczek J
Leuk Lymphoma; 2021 Dec; 62(13):3226-3234. PubMed ID: 34396931
[TBL] [Abstract][Full Text] [Related]
34. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
[TBL] [Abstract][Full Text] [Related]
35. [Significance of
Cheng P; Guan J; Zhou Y; Wang QX; Wang LL; Zhang T; Cheng H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):164-170. PubMed ID: 38387916
[TBL] [Abstract][Full Text] [Related]
36. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
Gahrton G; Iacobelli S; Björkstrand B; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Carella AM; Beksac M; Bosi A; Milone G; Corradini P; Schönland S; Friberg K; van Biezen A; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Garderet L; Kröger N;
Blood; 2013 Jun; 121(25):5055-63. PubMed ID: 23482933
[TBL] [Abstract][Full Text] [Related]
37. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas].
Wang QL; Huang HW; Jin ZM; Tang XW; Qiu HY; Fu CC; Han Y; Miao M; Chang HR; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):952-956. PubMed ID: 27995879
[TBL] [Abstract][Full Text] [Related]
39. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
Giralt S; Costa LJ; Maloney D; Krishnan A; Fei M; Antin JH; Brunstein C; Geller N; Goodman S; Hari P; Logan B; Lowsky R; Qazilbash MH; Sahebi F; Somlo G; Rowley S; Vogl DT; Vesole DH; Pasquini M; Stadtmauer E
Biol Blood Marrow Transplant; 2020 Apr; 26(4):798-804. PubMed ID: 31756536
[TBL] [Abstract][Full Text] [Related]
40. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
